This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n14http://linked.opendata.cz/resource/drugbank/drug/DB08992/identifier/kegg-drug/
n13http://linked.opendata.cz/resource/drugbank/drug/DB08992/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/patent/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n11http://linked.opendata.cz/resource/drugbank/drug/DB08992/identifier/chebi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://www.drugs.com/international/
n12http://linked.opendata.cz/resource/drugbank/drug/DB08992/identifier/wikipedia/
n8http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08992
rdf:type
n3:Drug
n3:description
Eperisone is an antispasmodic drug which relaxes both skeletal muscles and vascular smooth muscles, and demonstrates a variety of effects such as reduction of myotonia, improvement of circulation, and suppression of the pain reflex. It is not approved for use in the United States, but is available in other countries like India, South Korea, and Bangladesh.
n3:generalReferences
# Cabitza P, Randelli P: Efficacy and safety of eperisone in patients with low back pain: a double blind randomized study. Eur Rev Med Pharmacol Sci. 2008 Jul-Aug;12(4):229-35. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18727454 # Jeoung MK, Jeong ES, Kim NH, Kim CS, Chung YB, Lee YM, Ahn SY, Cho HE, Lee YH, Hong JT, Moon DC: Determination of eperisone in human plasma by liquid chromatography-ESI-tandem mass spectrometry. Arch Pharm Res. 2007 Sep;30(9):1174-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17958338
n3:group
investigational approved
owl:sameAs
n6:DB08992
dcterms:title
Eperisone
adms:identifier
n11:77069 n12:Eperisone n13:DB08992 n14:D01671
n3:patent
n9:3995047
n3:synonym
Epérisone Eperisonum Eperisona Eperison (2RS)-1-(4-ethylphenyl)-2-methyl-3-(1-piperidyl)propan-1-one
n3:salt
foaf:page
n17:eperisone.html
n3:IUPAC-Name
n4:271B62E2-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B62E8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B62E7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B62E4-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B62E5-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B62E6-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B62E0-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B62DE-363D-11E5-9242-09173F13E4C5 n4:271B62E1-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B62DF-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:M03BX09
n3:H-Bond-Acceptor-Count
n4:271B62EE-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B62EF-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B62E9-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B62EA-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B62EC-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B62EB-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B62ED-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
56839-43-1
n3:Bioavailability
n4:271B62F4-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B62F6-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B62F7-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B62F8-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B62F3-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B62F2-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B62F5-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B62E3-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B62F0-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B62F1-363D-11E5-9242-09173F13E4C5